A Study on How CagriSema Affects Levels of Atorvastatin and Warfarin in the Blood of Participants With Excess Body Weight

NCT06289504 · Completed

Last updated 2026-05-28

This clinical trial is testing how the medication CagriSema affects the levels of atorvastatin and warfarin in the blood of adults with excess body weight.

Status Completed The study has finished.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 34 people

Who can join Ages 18–65 · all sexes

Timeline Started 2024-02 · est. completion 2024-11

Where 1 site · Canada

What this study is testing ClinicalTrials.gov NCT06289504 ↗

Description as written by the study sponsor.

This study will look at how CagriSema affects the blood levels of atorvastatin and warfarin. The study will look at the levels of warfarin and atorvastatin in the blood before the participant starts taking CagriSema and if this changes after the participant has taken CagriSema. The study will also investigate the effect of warfarin before and after the participant takes CagriSema and assess if the injection site affects the level of CagriSema in the blood. The study will last for about 8 months.

Treatments tested

Cagrilintide Drug

Cagrilintide will be administered subcutaneously once weekly.
Semaglutide Drug

Semaglutide will be administered subcutaneously once weekly.
Atorvastatin Drug

Atorvastatin will be administered as a single dose orally 2 times during the study.
Warfarin Drug

Warfarin will be administered as a single dose orally 2 times during the study.

Main thing measured	AUC0-72hours,atorv,SD: Area under the atorvastatin plasma concentration-time curve from time 0 to 72 hours after a single dose of atorvastatin without CagriSema exposure and at CagriSema steady state
Sponsor	Novo Nordisk A/S
Conditions studied	Obesity
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06289504 ↗